Full Press Release Details
SAN FRANCISCO , Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr. Adi Diab , and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The event will follow Friday's oral presentation by Dr. Diab of preliminary data from the ongoing dose-escalation stage of the REVEAL Phase 1/2 clinical study evaluating the combination of TLR agonist, NKTR-262, with a CD122-preferential IL-2 pathway agonist, bempegaldesleukin* (NKTR-214), in patients with locally advanced or metastatic solid tumors.
| Details on the Analyst Call: | |
| Date and Time: Friday, March 1, 2019 at 3:00 p.m. Pacific Time | |
| Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international) | |
| Passcode: 6970019 |
The conference call will include lead investigator on the REVEAL study, Dr. Adi Diab , Assistant Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. The webcast and slides for the conference call can be accessed through a link that is posted on the Investors section of the Nektar website at https://ir.nektar.com/events-and-presentations/events . The event will also be available for replay for two weeks on the company's website, www.nektar.com .
| Details on the Oral Presentation at ASCO-SITC: | |
| Abstract Title: "Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 | |
| agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid | |
| tumors (REVEAL Phase Ib/II Trial)" | |
| Abstract: #28 | |
| Presenter: Dr. Adi Diab, MD Anderson Cancer Center | |
| Session: Oral Abstract Session B | |
| Date and Time: Friday, March 1, 2019, 1:00 p.m.-2:15 p.m. Pacific Time |
About Nektar Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at www.nektar.com .
* rINN (recommended International Nonproprietary Name)
SOURCE Nektar Therapeutics